Moreover, co-treatment with PRMT5 and PARP inhibitors restores antitumor activity in PARP inhibitor-resistant AML cells [599], while PRMT5 inhibition combined with AKT inhibitors synergistically suppresses the growth of diffuse large B-cell lymphoma [600]. Here, PARP1 is linked to acute myeloid leukemia.